Core Insights - Ardent Health, Inc. experienced a significant decline in share price, dropping over 33% in intraday trading on November 13, 2025, following the announcement of a $43 million decrease in revenue and a $54 million increase in professional liability reserves [1][3]. Financial Performance - The company reported a $43 million drop in revenue for Q3 2025, attributed to new insights from "hindsight evaluations of historical collection trends" and adjustments in estimating accounts receivable collectability [2]. - A $54 million rise in professional liability reserves was noted, linked to adverse prior period claim developments due to recent settlements and ongoing litigation in New Mexico [2]. Legal Investigation - Gibbs Mura is investigating a potential securities class action lawsuit against Ardent Health, focusing on possible violations of federal securities laws following the company's financial disclosures [1][6].

Nov 13, 2025 2:19 PM Eastern Standard Time ARDT BREAKING: Ardent Health, Inc. Revenue Drop Triggers Securities Fraud Investigation after Stock Plummets 33% -- Investors Urged to Contact BFA Law Share NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Ardent Health, Inc. (NYSE: ARDT) for potential violations of the federal securities laws. Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Ardent Health, Inc. ( ...

SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Ardent Health, Inc. (NYSE: ARDT) or certain of its officers and directors violated federal securities laws by making false or misleading statements and/or failing to disclose material information to investors. Background of the Investigation On November 12, 2025, Ardent issued a press release announcing its financial results for the third quarter of 2025. In connection with that release, th ...

Ardent Health (NYSE:ARDT) Q3 2025 Earnings Call November 13, 2025 09:00 AM ET Speaker5Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ardent Health Third Quarter 2025 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, si ...

Ardent Health (NYSE:ARDT) Q3 2025 Earnings Call November 13, 2025 09:00 AM ET Speaker0Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ardent Health Third Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session.I would now like to turn the conference ove ...

3Q25 Performance - Total revenue increased by 8.8% to $1.577 billion in 3Q25[14] - Adjusted EBITDA grew by 46.3% to $143 million in 3Q25[14] - Adjusted EBITDA margin expanded by 240 bps to 9.1% in 3Q25[14] - Operating cash flow increased by 72.1% to $154 million in 3Q25[14] Year-to-Date (YTD) Performance - Total revenue increased by 8.2% to $4.719 billion YTD[14] - Adjusted EBITDA increased by 30.1% to $411 million YTD[14] - Adjusted EBITDA margin expanded by 150 bps to 8.7% YTD[14] - Operating cash flow increased by 26.4% to $247 million YTD[14] Volume and Revenue Drivers - Admissions increased by 5.8% in 3Q25 and 6.7% YTD[12] - Adjusted admissions increased by 2.9% in 3Q25 and 2.4% YTD[12] - Net patient service revenue per adjusted admission grew by 5.8% to $17,252 in 3Q25[14] Full-Year 2025 Guidance - Total revenue guidance reaffirmed at $6.2 billion to $6.45 billion[25] - Adjusted EBITDA guidance revised to $530 million to $555 million[25] - Adjusted admissions growth expected to be between 2.0% and 3.0%[25]

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.Shares of Ardent Health, Inc. (NYSE:ARDT) fell sharply in pre-market trading after the company reported third-quarter earnings below estimates and lowered its FY2025 GAAP EPS guidance.Ardent Health Partners reported quarterly losses of 17 cents per share which missed the analyst consensus estimate of earnings of 41 cents per share. The company reported quarterly sales of $1.577 billion which beat the analyst con ...

分组1 - Ardent Health, Inc. reported quarterly earnings of $0.52 per share, exceeding the Zacks Consensus Estimate of $0.42 per share, and showing a significant increase from $0.19 per share a year ago, representing an earnings surprise of +23.81% [1] - The company achieved revenues of $1.58 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.55%, and an increase from $1.45 billion in the same quarter last year [2] - Over the last four quarters, Ardent Health has consistently surpassed consensus EPS estimates four times and topped revenue estimates three times [2] 分组2 - The stock has underperformed the market, losing about 17.7% since the beginning of the year, while the S&P 500 has gained 16.4% [3] - The current consensus EPS estimate for the upcoming quarter is $0.61 on revenues of $1.65 billion, and for the current fiscal year, it is $1.82 on revenues of $6.35 billion [7] - The Zacks Industry Rank indicates that the Medical Services sector is currently in the bottom 41% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Financial Performance - Total revenue for Q3 2025 was $1.58 billion, representing an 8.8% year-over-year growth[3] - Net loss attributable to Ardent Health was $23 million, or $0.17 per diluted share, compared to a net income of $26 million, or $0.19 per diluted share in Q3 2024[10] - Adjusted EBITDA increased by 46.3% year-over-year to $143 million[10] - Total revenue for Q3 2025 was $1,576,746, an increase of 8.8% compared to $1,449,817 in Q3 2024[29] - Net income attributable to Ardent Health, Inc. for Q3 2025 was a loss of $23,478, compared to a profit of $26,322 in Q3 2024[29] - Total revenue for the nine months ended September 30, 2025, was $4,719,260,000, reflecting an 8.2% increase from $4,359,783,000 in 2024[38] Operational Metrics - Admissions grew by 5.8% year-over-year, with adjusted admissions increasing by 2.9%[11] - Total surgeries increased by 1.4% year-over-year, driven by a 9.7% growth in inpatient surgeries[11] - Admissions increased by 6.7% to 124,786 for the nine months ended September 30, 2025, compared to 116,995 in 2024[38] - Inpatient surgeries rose by 7.4% to 28,822 in 2025, up from 26,829 in 2024[38] - Average length of stay increased to 4.68 days in 2025 from 4.62 days in 2024, a 1.3% increase[38] Financial Guidance - The company is revising its 2025 adjusted EBITDA guidance to $530 million to $555 million, reflecting a 9% increase from 2024[12] - The company reaffirmed its full-year 2025 revenue guidance of $6,200 million to $6,450 million, indicating a 6% growth from 2024[14] - The company provided guidance for adjusted EBITDA for the full year ending December 31, 2025, in the range of $530 million to $555 million[58] Cash Flow and Liquidity - Operating cash flow for Q3 2025 was $154 million, up from $90 million in Q3 2024[9] - Net cash provided by operating activities increased to $247,075,000 in 2025 from $195,457,000 in 2024, representing a 26.4% increase[34] - Cash and cash equivalents at the end of the period rose to $609,441,000, up from $563,142,000 at the end of 2024[34] - The company had total cash and cash equivalents of $609 million and total debt of $1.1 billion as of September 30, 2025[8] Expenses and Liabilities - Total operating expenses for Q3 2025 were $1,578,949, up from $1,392,750 in Q3 2024, reflecting a 13.4% increase[29] - Salaries and benefits accounted for 42.9% of total revenue in Q3 2025, compared to 43.8% in Q3 2024[29] - Total liabilities increased to $3,522,526,000 as of September 30, 2025, from $3,433,743,000 as of December 31, 2024[36] Risks and Challenges - The company faces risks including changes in healthcare policy, reimbursement rates, and economic conditions that could impact future performance[24] - A significant increase in professional liability reserves of $54.468 million was recorded, primarily due to adverse prior-period claim developments in New Mexico[48] Other Financial Metrics - Interest expense for Q3 2025 was $13,914, slightly down from $14,629 in Q3 2024[29] - Adjusted EBITDAR is used as a valuation measure, excluding certain expenses to allow comparison with other healthcare companies[21] - The change in accounting estimate resulted in a reduction of total revenue by $42.6 million, impacting noncontrolling interest earnings by $0.7 million[47] - Restructuring, exit, and acquisition-related costs amounted to $3.040 million for the three months ended September 30, compared to $3.796 million in the prior year[46] - Cybersecurity incident recoveries, net, were reported at $(2.950) million for the three months ended September 30, down from $(4.976) million in the previous year[52]

Summary of Ardent Health Conference Call Company Overview - **Company**: Ardent Health (NYSE: ARDT) - **Industry**: Healthcare Services, specifically hospital operations - **Key Executives**: Marty Bonick (CEO), Alfred Lumsdaine (CFO) Core Points and Arguments - **Growth Strategy**: Ardent Health is focused on growth, operating 30 hospitals and over 280 assets across eight urban markets. The company aims to expand beyond traditional hospital services into urgent care, ambulatory surgery centers (ASCs), and imaging centers [3][4] - **Market Dynamics**: The markets in which Ardent operates are growing at an average rate three times faster than the U.S. average, with a targeted long-term top-line growth of 5% to 6% [8][25] - **EBITDA Margin Goals**: The company aims to expand EBITDA margins by 100 to 200 basis points over the next three to four years, targeting mid-teens EBITDA margins [7][16] - **Impact of OBBA**: The OBBA is projected to have a $150 to $175 million EBITDA impact, but Ardent expects to mitigate this through various initiatives, including the Rural Health Transformation Fund [9][10][11] - **Technological Investments**: Significant investments in technology, including partnerships with Ensemble Health Partners and the implementation of Epic EHR, are expected to enhance operational efficiency and revenue cycle management [35][38][40] Additional Important Insights - **Partnership Model**: Ardent's partnership model with academic and nonprofit organizations is seen as a key differentiator, allowing for shared growth and resource optimization [43][45] - **Volume Trends**: The company does not subscribe to the notion of elevated utilization post-COVID, instead indicating a return to normal trends with an aging population contributing to increased demand for services [24][25] - **Health Insurance Exchange**: Approximately 7.1% of Ardent's revenue comes from health exchanges, which has seen growth but is less lucrative compared to commercial business [21][22] - **Operational Efficiencies**: The company is focusing on service line rationalization and shifting lower acuity volumes to outpatient settings to enhance margins [32][33] - **Future Outlook**: Ardent is optimistic about its ability to navigate regulatory uncertainties and believes its differentiated joint venture model positions it well for future growth [47] This summary encapsulates the key points discussed during the Ardent Health conference call, highlighting the company's growth strategies, market dynamics, and operational efficiencies while addressing potential challenges and future outlook.